How We Got Here: Baxalta And Shire Reach Final Merger Hurdle
This article was originally published in Scrip
Following Baxalta Inc.'s announcement that it will hold a special meeting of stockholders on May 27 for investors to cast the final vote on its merger agreement with specialty biopharma company Shire, Scrip has taken a look back over the last year to see how this $32bn deal got made.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.